In the BioHarmony Drug Report Database
Brolucizumab
Beovu (brolucizumab) is an antibody pharmaceutical. Brolucizumab was first approved as Beovu on 2019-10-07. It is used to treat wet macular degeneration in the USA. It has been approved in Europe to treat wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A.
Trade Name
|
Beovu |
|---|---|
Common Name
|
brolucizumab |
ChEMBL ID
|
CHEMBL3707357 |
Indication
|
wet macular degeneration |
Drug Class
|
Monoclonal antibodies: humanized, cardiovascular indications |
Image (chem structure or protein)
